You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management
Login
Username:

Password:


Related Headlines

Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management

Tonix Pharmaceuticals receives FDA clearance for Phase 2 study of major depressive disorder treatment

Enlivex Therapeutics reports sustained six-month efficacy for Allocetra in Phase IIa knee osteoarthritis trial

Riyadh's 10th SPNS Conference Focuses on AI and Technology as Catalysts for Better Paediatric Neurology Care

OrthoCarolina Research Institute Marks Major Achievements and Calls for Community Support in Orthopedic Innovation

Inspiring Children Foundation honours NAMI CEO Daniel H Gillison, Jr

AGC Biologics to manufacture AAVantgarde's dual-vector gene therapies for inherited retinal diseases

HitGen signs new funding agreement with Gates Foundation

Nuvalent's zidesamtinib NDA filing accepted by US FDA

Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial

Frost & Sullivan honours WuXi AppTec

Hemispherian secures US patent allowance expanding GLIX1 patent protection

Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA

AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination

European Commission approves Insmed's BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025